The invention relates to a cosmetic composition comprising one or more pyridinedicarboxylic acid derivatives of general formula (I) or a salt thereof and one or more antioxidants chosen from flavone heterosides, polyhydroxylated stilbenes, pyrimidinecarboxylic acid derivatives and ascorbic acid esters.
##STR00001##
|
1. A cosmetic composition comprising:
one pyridinedicarboxylic acid derivative which is
diethyl 2,4-pyridinedicarboxylate,
and
one antioxidant which is resveratrol.
6. A cosmetic process for treating human keratin fibres and/or the scalp, comprising the application to said fibres and/or the scalp of a composition comprising:
one pyridinedicarboxylic acid derivative which is
diethyl2,4-pyridinedicarboxylate,
and
one antioxidant which is resveratrol.
7. A method for inducing and/or stimulating the growth of human keratin fibres, and/or for curbing their loss, the method comprising applying a composition comprising:
one pyridinedicarboxylic acid derivative which is
diethyl2,4-pyridinedicarboxylate,
and
one antioxidant which is resveratrol.
2. The cosmetic composition according to
3. The cosmetic composition according to
4. The cosmetic composition according to
5. The cosmetic composition according to
8. The method according to
|
|||||||||||||||||||||||||||||||||||
This is a national stage application of PCT/EP2015/080830, filed internationally on Dec. 21, 2015, which claims priority to French Application No. 1463104, filed on Dec. 22, 2014, both of which are incorporated by reference herein in their entireties.
The present invention relates to a cosmetic composition comprising at least one particular pyridinedicarboxylic acid derivative, or a salt thereof, and at least one antioxidant chosen from flavone heterosides, polyhydroxylated stilbenes, pyrimidinecarboxylic acid derivatives and ascorbic acid esters, and also to the use thereof for inducing and/or stimulating the growth of human keratin fibres such as the hair and the eyelashes and/or for curbing their loss.
The invention also relates to a cosmetic process for treating human keratin fibres using said composition.
The growth of the hair and its renewal are mainly determined by the activity of the hair follicles and their matrix environment. Their activity is cyclical and essentially comprises three phases, namely the anagenic phase, the catagenic phase and the telogenic phase.
The anagenic phase (active or growth phase), which lasts several years and during which the hairs lengthen, is followed by a very short and transient catagenic phase which lasts a few weeks, and then by a telogenic phase or resting phase which lasts a few months. At the end of the resting period, the hairs fall out and another cycle begins again. The head of hair is thus undergoing constant renewal and, of the approximately 150 000 hairs which make up a head of hair, approximately 10% are at rest and will be replaced in the months to come. The natural loss of the hair can be estimated, on average, at a few hundred hairs per day for a normal physiological state. This constant physical renewal process undergoes a natural change during the course of ageing; the hairs become finer and their cycles shorter. In addition, various causes may bring about substantial temporary or definitive hair loss. Hair loss, in particular alopecia, is essentially due to disruptions in hair renewal. These disruptions lead in a first stage to acceleration of the frequency of the cycles at the expense of the quality of the hairs, and then of their quantity. Progressive miniaturization of the bulbs takes place, in conjunction with isolation of these bulbs by gradual thickening of the perifollicular collagen matrix and also of the outer connective sheath. Revascularization around the hair follicle is thus made more difficult cycle after cycle. The hairs regress and become miniaturized until they are no more than an unpigmented down, and this phenomenon leads to gradual thinning of the head of hair. The number and mean diameter of the hair follicles that constitute the head of hair are affected. Certain areas are preferentially affected, especially the temporal or frontal lobes in men, and diffuse alopecia of the crown is observed in women.
The term “alopecia” also covers an entire family of hair follicle complaints whose final consequence is partial or general definitive hair loss. It may more particularly be a case of androgenic alopecia. In a large number of cases, early hair loss occurs in genetically predisposed individuals, which is known as andro-chrono-genetic alopecia; this form of alopecia especially concerns men. It is moreover known that certain factors, such as hormonal imbalance, physiological stress or malnutrition, can accentuate the phenomenon. In addition, loss or impairment of the hair can be in connection with seasonal phenomena.
Loss of hair density and hair loss are often experienced as distressing by persons thereby affected, especially when they are still young.
Pharmacological active agents such as minoxidil, latanoprost, fluridil, spironolactone and combinations thereof are known. However, they do not make it possible to maintain totally satisfactory hair density and may have adverse side effects.
Other products belonging to the cosmetic field exist. Among these, examples that may be mentioned include Aminexil® and Stemoxydine®.
However, consumers are still in search of more efficient products that have no adverse side effects, which would delay the process of “loss of hair density” or “excessive hair loss”.
The Applicant has found, surprisingly and advantageously, that the combination of at least one pyridinedicarboxylic acid derivative of formula (I) as described below, or a salt thereof, with at least one antioxidant chosen from flavone heterosides, polyhydroxylated stilbenes, pyrimidinecarboxylic acid derivatives and ascorbic acid esters produces improved hypoxia-mimicking effects when compared with such a derivative of formula (I) alone or its combination with vitamin C.
This derivative is especially described in European patent application No. 1 352 629. An example of this derivative is sold under the trade name Stemoxydine® by the company L'Oreal.
Advantageously, the combination of the invention makes it possible to obtain improved effects on the head of hair especially regarding the hair density, the diameter or any other parameter that improves the quality of the head of hair, when compared with the use of stemoxydine alone.
One subject of the invention is thus a cosmetic composition comprising:
##STR00002##
The present invention also relates to a cosmetic process for treating human keratin fibres and/or the scalp, comprising the application of the composition according to the invention to said fibres such as the hair and the eyelashes, and/or the scalp.
A subject of the invention is also the use of the cosmetic composition, for inducing and/or stimulating the growth of human keratin fibres such as the hair and the eyelashes, and/or for curbing their loss, and in particular for treating androgenic alopecia.
Other subjects, characteristics, aspects and advantages of the invention will emerge even more clearly on reading the description and the example that follows.
In the text hereinbelow, and unless otherwise indicated, the limits of a range of values are included within that range, especially in the expressions “between” and “ranging from . . . to . . . ”. Moreover, the expression “at least one” used in the present description is equivalent to the expression “one or more”.
According to the invention, the cosmetic composition comprises:
##STR00003##
The C1-C18 alkyl group is preferably a saturated or unsaturated alkyl group comprising from 1 to 10 carbon atoms, such as methyl, ethyl, tert-butyl, isopropyl or hexyl. The alkyl group may contain at least one carbon-carbon double bond or carbon-carbon triple bond, for instance —CH═CH2, —CH2—CH═CH—CH3 or —CH2—C≡CH.
According to the present invention, the term “alkoxy” means a group —O—R in which R is a C1-C18 alkyl group as defined previously.
The term “acyloxy” means a group —O—CO—R in which R is a C1-C18 alkyl group as defined previously.
The term “alkylamino” means a group —NH—R in which R is a C1-C18 alkyl group as defined previously.
The aryl group may represent the phenyl or naphthyl group.
When R′ and R″ together represent a heterocycle, they may represent a ring of 4 to 7 atoms and better still of 5 to 6 atoms, comprising from 1 to 4 heteroatoms chosen from O, S and N, this ring possibly being saturated or unsaturated. Heterocycles that may be mentioned include piperidine, morpholine, imidazole, pyrazole, piperazine, pyrrolidine and thiazolidine.
In particular, R′ and R″ represent a C1-C18 and better still C1-C10 alkyl group optionally substituted with an alkoxy or acyloxy group.
In formula (I), R1 and R2 preferably represent, independently of each other, —OH, —OCH3, —O—CH2—CH3, —O—CH(CH3)2, —O—CH 2—O—COCH3, —NH—CH2—CH2—CH3, —NH—CH2—CH2OH, —NH—CH2—CH2—CH2OH and —NH—CH2—CH2OCH3.
In one particular embodiment, —COR1 and —COR2 are, respectively, in positions 2 and 3, or 2 and 4, of the pyridine nucleus. However, they may be in positions 2 and 5.
According to the invention, the term “salts of the derivative of formula (I)” means the mineral or organic salts of a derivative of formula (I).
As mineral salts that may be used according to the invention, mention may be made of the sodium or potassium double salts and also the zinc (Zn2+), calcium (Ca2+), copper (Cu2+), iron (Fe2+), strontium (Sr2+), magnesium (Mg2+) or manganese (Mn2+) salts; hydroxides, carbonates and chlorides.
The organic salts that may be used according to the invention are, for example, the triethanolamine, monoethanolamine, diethanolamine, hexadecylamine, N,N,N′,N′-tetrakis(2-hydroxypropyl)ethylenediamine and tris(hydroxymethyl)aminomethane salts.
Unless otherwise mentioned in the present description, the use of the expression “pyridinedicarboxylic acid derivative” includes the derivative in salified or non-salified form.
Examples of pyridinedicarboxylic acid derivatives that may especially be mentioned include:
Advantageously, the pyridinedicarboxylic acid derivative is in pyridinedicarboxylic acid ester form. The particularly preferred derivative is diethyl 2,4-pyridinedicarboxylate. It is sold, for example, under the trade name Stemoxydine® by the company L'Oreal.
The derivative(s) or a salt thereof are present in an amount preferably ranging from 10−3% to 10% by weight, better still from 0.1% to 8% by weight and even more preferentially from 0.5% to 5% by weight, relative to the total weight of the composition.
The oxidizing agent(s) used in the composition according to the present invention are chosen from flavone heterosides, polyhydroxylated stilbenes, pyrimidinecarboxylic acid derivatives and ascorbic acid esters.
Examples of flavone heterosides that may especially be mentioned include baicalin, apigetrin, rhofolin, vitexin, tetuin and apiin.
Examples of polyhydroxylated stilbenes that may especially be mentioned include resveratrol or else pinosylvin.
An example of a pyrimidinecarboxylic acid derivative that may especially be mentioned is ectoin.
Examples of ascorbic acid esters that may especially be mentioned include ascorbyl palmitate, ascorbyl linoleate, ascorbyl oleate and magnesium 2-ascorbyl phosphate.
Preferably, the antioxidants(s) are chosen from baicalin, resveratrol, ectoin and ascorbyl palmitate, and mixtures thereof.
The antioxidants(s) are present in an amount preferably ranging from 0.1% to 15% by weight, even better still from 0.5% to 10% by weight and even more preferentially from 0.7% to 6% by weight, relative to the total weight of the composition.
The composition according to the invention is preferably aqueous and then comprises water at a concentration preferably ranging from 5% to 98% by weight, especially from 20% to 95% by weight and better still from 50% to 95% by weight, relative to the total weight of the composition.
The composition may also comprise one or more organic solvents that are liquid at 25° C. and 1.013×105 Pa and which are especially water-soluble, such as C1-C7 alcohols, especially C1-C7 aliphatic or aromatic monoalcohols, and C3-C7 polyols and polyol ethers, which may thus be used alone or as a mixture with water. Advantageously, the organic solvent may be chosen from ethanol, isopropanol and propylene glycol, and mixtures thereof.
The composition of the invention is preferably a composition intended for cosmetic use in topical application to the skin and keratin fibres, and more especially to the scalp, the hair and the eyelashes.
According to the application method, this composition may be in any galenical form normally used in cosmetics, such as a lotion, serum, milk, O/W or W/O cream, gel, ointment, pomade, powder, balm, patch, impregnated pad, soap, bar or foam.
For topical application to the skin, including the scalp, the composition may especially be in the form of an aqueous, alcoholic or aqueous-alcoholic solution or suspension, an oily suspension or solution, an emulsion or dispersion of liquid or semi-liquid consistency obtained by dispersing a fatty phase in an aqueous phase (O/W) or vice versa (W/O), a dispersion or emulsion of soft consistency, an aqueous or aqueous-alcoholic or oily (anhydrous) gel, a loose or compact powder to be used as is or to be incorporated into a physiologically acceptable medium (excipient), or alternatively microcapsules or microparticles, or vesicular dispersions of ionic and/or nonionic type.
It is also possible to envisage a composition in the form of a foam or alternatively in the form of an aerosol composition also comprising a pressurized propellant.
In particular, the composition for application to the scalp or the hair may be in the form of a haircare lotion, for example for daily or twice-weekly application, a shampoo or a hair conditioner, in particular for twice-weekly or weekly application, a liquid or solid soap for cleansing the scalp for daily application, a hairstyle shaping product (lacquer, hairsetting product, styling gel), a treatment mask, a cream or a foaming gel for cleansing the hair. It may also be in the form of a hair dye or a hair mascara to be applied by brush or comb.
According to a particular embodiment, the composition is in the form of a hair cream or lotion, a shampoo, a hair conditioner, a hair mascara or a mascara for the eyelashes.
The composition according to the invention may also contain adjuvants that are common in cosmetics, which are conventionally used in an amount ranging from 0.01% to 20% and better still from 0.1% to 10% of the total weight of the composition.
The present invention also relates to a cosmetic process for treating human keratin fibres and/or the scalp, comprising the application of a composition according to the invention to the fibres and/or the scalp, and more particularly the hair, the eyelashes and/or the scalp.
In particular, the process comprises the steps of applying a composition according to the invention to the scalp and/or the fibres, and optional rinsing. In the case of rinsing, the leave-on time of the composition may range from 1 minute to 30 minutes.
Preferably, the cosmetic composition according to the invention is not rinsed off.
The examples that follow serve to illustrate the invention.
The following protocol was followed: the tests were performed on human keratinocytes in culture, seeded on Greiner brand 48-well plates, coated with bovine collagen I.
The plates were prepared according to the following procedure: the solution of bovine collagen I at 0.1 mg/ml was prepared by dilution in phosphate-buffered saline (PBS) of the bovine collagen I solution sold by the company Life Technologies. Each well was immersed with 1 ml of this dilution, which was left at the bottom of the wells for 1 hour at 37° C. At the end of the incubation, the collagen solution was removed and the wells were rinsed twice with 1 ml of PBS. The plates were then stored at 4° C. until the time of use.
The tests are performed using primary human keratinocytes at a rate of 23 800 cells/cm2 of wells coated with bovine collagen I as explained previously, followed by culturing for 72 hours in the presence of 500 μl of KGM medium sold by the company Lonza, supplemented with:
The cells were then treated with the various compounds (stemoxydine, vitamin C, resveratrol, baicalin, ectoin, ascorbyl palmitate and mixtures thereof with stemoxydine) in concentrations ranging up to the highest non-cytotoxic concentration, for 72 hours under normoxia (21% oxygen).
Following this culturing and treatment, the cell lawns were washed with phosphate-buffered saline (or PBS) and then lysed using a lysis buffer proposed in the kit from the supplier Qiagen. The RNAs were then extracted using the RNeasy isolation kit and the Qiacube robotic workstation, both sold by the company Qiagen, according to the manufacturer's instructions.
The quantity and quality of RNAs were controlled using the LabChip® GX bioanalyser from Perkin-Elmer before performing reverse transcription (RT) using the Qiagen kit and according to the supplier's recommendations (QuantiTect reverse transcription kit). The cDNA obtained following the RT was then amplified by real-time quantitative PCR using a specific kit sold under the commercial brand LightCycler® 480 SYBR Green Master Mix by the company Roche (Cat. No. 14123920) and an LC480 thermocycler (Roche). The PCRs were performed in triplicate (n=3). The information relating to the primers used is presented below.
Priming was performed using specific standard primers sold by the company Qiagen, the references for which are BNIP3/QT00024178/Hs_BNIP3-1-SG Quantitect Assay Primer; CA9/QT00011697/Hs_CA9-1-SG Quantitect Assay Primer; EGNL3/QT00025900/Hs_EGNL3-1-SG Quantitect Assay Primer; RPL13A/QT00089915/Hs_RPL13A-1-SG Quantitect Assay Primer, and the fluorescent probe of brand name SYBR Green sold by the company specified previously.
The PCR was performed in three phases:
The incorporation of SYBR Green into the amplified DNA was measured continuously during the amplification cycles. These measurements make it possible to obtain curves of fluorescence intensity as a function of the PCR cycles and thus to evaluate the relative expression of each marker from the cycle thresholds (Ct), corresponding to the number of cycles required to appropriately detect a fluorescence level. For each marker and for each condition, the relative expression (RE) value was normalized relative to the expression of the reference gene RPL13.
The expression of each gene is normalized by that of the “stable referent gene” (or “housekeeping gene” RPL13A, ribosomal gene). The results (“fold change” (Fc)) are expressed relative to the control.
The genes used are hypoxia-sensitive (HIF-1 alpha signalling pathway) and are collated in Table 1 below.
TABLE 1
Accession
Name
Abbreviation
number
Function
Carbonic
CA9
NM_001216
Regulation of the
anhydrase IX
intracellular pH
BCL2/adenovirus
BNIP3
NM_004052
Control of the
E1B 19 kDa-
cell apoptosis
interacting
protein
Prolyl
EGLN3 (or
NM_022073
Hydroxylation of
hydroxylase
Egg-laying
collagen and HIF-
nine homolog
1alpha
3, or PHD3)
Ribosomal
RPL13
NM_000977
Referent gene
protein L13
Three hypoxia-sensitive genes (BNIP3, EGLN3 and CA9) were used in the following examples. Three tests were performed according to the protocol described above for each gene and for each compound or combination. The results are expressed as a function of the expression of the referent gene RPL13 (control) (1.00) and indicated in the tables below, the mean and the standard deviation being indicated in parentheses.
TABLE 2
Vitamin C
Vitamin C
Stemoxydine
Gene
100 μM
10 μM
300 μM
Control
BNIP3
0.98/1.32/1.07
1.02/1.13/0.89
1.51/1.65/2.13
1 ± 0
(1.12 ± 0.18)
(1.01 ± 0.12)
(1.76 ± 0.32)
EGLN3
1.05/1.51/1.16
0.92/1.41/0.89
2.15/2.09/3.56
1 ± 0
(1.24 ± 0.24)
(1.07 ± 0.29)
(2.60 ± 0.83)
CA9
1.43/1.51/0.74
1.19/1.43/0.43
3.87/3.86/5.86
1 ± 0
(1.22 ± 0.42)
(1.02 ± 0.52)
(4.53 ± 1.15)
Vitamin C 100 μM +
Vitamin C 10 μM +
Gene
Stemoxydine 300 μM
Stemoxydine 300 μM
BNIP3
1.72/1.98/2.3
1.63/1.9/2
(2 ± 0.23)
(1.84 ± 0.19)
EGLN3
3.01/3.35/4.33
2.15/2.64/2.43
(3.56 ± 0.68)
(2.40 ± 0.24)
CA9
6.39/6.74/8.13
5.33/4.8/4.93
(7.09 ± 0.92)
(5.02 ± 0.28)
TABLE 3
Resveratrol
Resveratrol
Stemoxydine
Genes
1 μM
0.3 μM
300 μM
Control
BNIP3
1.10/2.35/2.57
1.05/1.53/1.21
1.51/1.65/2.13
1 ± 0
(2.01 ± 0.79)
(1.26 ± 0.24)
(1.76 ± 0.32)
EGLN3
1.62/4.65/4.69
1.31/2.36/2.10
2.15/2.09/3.56
1 ± 0
(3.65 ± 1.76)
(1.92 ± 0.55)
(2.60 ± 0.83)
CA9
2.34/1.97/1.75
1.82/1.75/1.31
3.87/3.86/5.86
1 ± 0
(2.02 ± 0.33)
(1.63 ± 0.28)
(4.53 ± 1.15)
Resveratrol 1 μM +
Resveratrol 0.3 μM +
Genes
Stemoxydine 300 μM
Stemoxydine 300 μM
BNIP3
2.28/4.68/7.23
1.9/2.21/3.39
(4.73 ± 2.48)
(2.5 ± 0.79)
EGLN3
5.04/13.13/13.18
4.68/5.46/11.53
(10.45 ± 4.69)
(7.22 ± 3.75)
CA9
8.99/10.87/10.38
9.98/7.96/11
(10.08 ± 0.98)
(9.65 ± 1.55)
The results show a synergistic effect on the expression of the genes BNIP3, EGLN3 and CA9 when stemoxydine is combined with resveratrol. In addition, these effects are higher than those for the stemoxydine+vitamin C combination.
TABLE 4
Baicalin
Baicalin
Stemoxydine
Gene
30 μM
3 μM
300 μM
Control
BNIP3
1.14/1.41/1.15
0.99/1.27/1.06
1.51/1.65/2.13
1 ± 0
(1.23 ± 0.15)
(1.11 ± 0.15)
(1.76 ± 0.32)
EGLN3
1.70/2.47/2.03
1.00/1.33/1.25
2.15/2.09/3.56
1 ± 0
(2.07 ± 0.39)
(1.19 ± 0.17)
(2.60 ± 0.83)
CA9
1.06/1.07/0.6
1.27/1.18/0.74
3.87/3.86/5.86
1 ± 0
(0.91 ± 0.27)
(1.06 ± 0.28)
(4.53 ± 1.15)
Baicalin 30 μM +
Baicalin 3 μM +
Gene
Stemoxydine 300 μM
Stemoxydine 300 μM
BNIP3
2.10/2.19/2.07
2.10/1.99/2.77
(2.12 ± 0.06)
(2.29 ± 0.42)
EGLN3
5.94/8.65/5.87
4.61/3.88/6.21
(6.82 ± 1.59)
(4.90 ± 1.19)
CA9
8.25/7.95/7.71
8.89/6.75/9.23
(7.97 ± 0.27)
(8.29 ± 1.34)
The results show a synergistic effect on the expression of the genes BNIP3, EGLN3 and CA9 when stemoxydine is combined with baicalin. In addition, these effects are higher than those for the stemoxydine+vitamin C combination.
TABLE 5
Ascorbyl
Ascorbyl
palmitate
palmitate
Stemoxydine
Gene
30 μM
10 μM
300 μM
Control
BNIP3
1.04/1.6/0.81
1.01/1.35/0.95
1.51/1.65/2.13
1 ± 0
(1.15 ± 0.41)
(1.10 ± 0.22)
(1.76 ± 0.32)
EGLN3
1.02/2.04/0.43
1.4/1.78/0.87
2.15/2.09/3.56
1 ± 0
(1.16 ± 0.81)
(1.35 ± 0.46)
(2.60 ± 0.83)
CA9
1.09/1.73/0.14
1.65/2.00/1.25
3.87/3.86/5.86
1 ± 0
(0.99 ± 0.80)
(1.63 ± 0.38)
(4.53 ± 1.15)
Ascorbyl palmitate
Ascorbyl palmitate
30 μM +
10 μM +
Gene
Stemoxydine 300 μM
Stemoxydine 300 μM
BNIP3
2.21/2.51/2.34
2.42/2.25/2.50
(2.35 ± 0.15)
(2.39 ± 0.13)
EGLN3
4.05/3.93/3.50
5.42/3.77/4.82
(3.83 ± 0.29)
(4.67 ± 0.84)
CA9
8.23/8.21/6.56
9.42/8.36/11.14
(7.67 ± 0.96)
(9.64 ± 1.40)
The results show a synergistic effect on the expression of the genes BNIP3, EGLN3 and CA9 when stemoxydine is combined with vitamin C palmitate. These effects are higher in all respects than those for the stemoxydine+vitamin C combination.
TABLE 6
Ectoin
Ectoin
Stemoxydine
Gene
300 μM
100 μM
300 μM
Control
BNIP3
1.40/1.79/1.66
1.31/1.77/1.77
1.51/1.65/2.13
1 ± 0
(1.62 ± 0.2)
(1.62 ± 0.27)
(1.76 ± 0.32)
EGLN3
2.07/2.82/2.97
2.48/2.76/3.46
2.15/2.09/3.56
1 ± 0
(2.62 ± 0.48)
(2.90 ± 0.50)
(2.60 ± 0.83)
CA9
2.23/2.54/2.93
2.73/2.55/3.74
3.87/3.86/5.86
1 ± 0
(2.57 ± 0.35)
(3.01 ± 0.64)
(4.53 ± 1.15)
Ectoin 300 μM +
Ectoin 100 μM +
Gene
Stemoxydine 300 μM
Stemoxydine 300 μM
BNIP3
2.30/2.56/2.98
2.20/2.37/2.65
(2.61 ± 0.34)
(2.41 ± 0.23)
EGLN3
3.88/3.51/4.01
5.03/3.56/4.18
(3.80 ± 0.26)
(4.25 ± 0.74)
CA9
6.86/5.86/7.27
8.38/5.87/7.56
(6.66 ± 0.73)
(7.27 ± 1.28)
The results show a synergistic effect on the expression of the genes BNIP3, EGLN3 and CA9 when stemoxydine is combined with ectoin.
The compositions of the invention may be used, for example, as a lotion applied at a rate of 1 ml of lotion to the scalp, at a frequency of one to two times per day. The compositions described below may also be thickened using a thickening polymer.
Diethyl 2,4-pyridinedicarboxylate
0.5 g to 5 g
Resveratrol
0.2 g
Propylene glycol
10.0 g
Isopropyl alcohol
qs 100.0 g
Diethyl 2,4-pyridinedicarboxylate
0.5 g to 5 g
Ascorbyl palmitate
2 g
Propylene glycol
10.0 g
Isopropyl alcohol
qs 100.0 g
| Patent | Priority | Assignee | Title |
| Patent | Priority | Assignee | Title |
| 4717727, | Aug 31 1984 | Hoechst Aktiengesellschaft | Esters of pyridine-2,4- and 2,5-dicarboxylic acid as medicaments for the inhibition of proline hydroxylase and lysine hydroxylase |
| 4927627, | Sep 24 1987 | Henkel Kommanditgesellschaft auf Aktien | Emulsion-form hydrogen peroxide preparations for the bleaching and oxidative dyeing of hair |
| 5219847, | Jun 12 1989 | Shiseido Company, Ltd. | Antipruritic composition |
| 5472617, | Oct 18 1986 | Baker Hughes Incorporated | Method of demulsifying crude oil and water mixtures with copolymers of acrylates or methacrylates and hydrophilic commonomers |
| 5472687, | Jul 18 1985 | Topical pyridine N-oxides | |
| 5582817, | Feb 03 1992 | Otsuka Pharmaceutical Co., Ltd.; Japan Immunoresearch Laboratories Co., Ltd. | Remedy for dermatopathy and metallothionein inducer |
| 5696313, | Apr 14 1995 | HERAEUS ELECTRO-NITE INTERNATIONAL N V | Lambda sensor with electric heater |
| 5786379, | Dec 01 1995 | Centre International de Recherches Dermatologiques Galderma | Adamantyl-substituted biaromatic compounds and pharmaceutical/cosmetic compositions comprised thereof |
| 5945441, | Jun 04 1997 | GLIAMED, INC | Pyrrolidine carboxylate hair revitalizing agents |
| 6020139, | Apr 25 1995 | MEDIQUEST THERAPEUTICS, INC | S-adenosyl methionine regulation of metabolic pathways and its use in diagnosis and therapy |
| 6150405, | Jul 18 1985 | Hair loss treatment with ascorbates | |
| 6399613, | Jul 17 1997 | RHONE-POULENC RORER S A | Pyrazine derivatives, their preparation and medicaments containing them |
| 7598278, | Apr 11 2002 | SOCIETE L OREAL S A | Administration of pyridinedicarboxylic acid compounds for stimulating or inducing the growth of human keratinous fibers and/or arresting their loss |
| 8431653, | Dec 16 2005 | Mitsubishi Electric Company, Inc. | Curing agent composition for epoxy resins and epoxy resin composition |
| 20030223945, | |||
| 20090215837, | |||
| 20100105741, | |||
| 20130131095, | |||
| CA2082076, | |||
| DE1242748, | |||
| EP176741, | |||
| EP433457, | |||
| EP583479, | |||
| EP1352629, | |||
| ES2354103, | |||
| FR2159400, | |||
| FR2677247, | |||
| FR2733053, | |||
| GB1354446, | |||
| GB1408036, | |||
| JP11506426, | |||
| JP1301612, | |||
| JP2001253808, | |||
| JP2001288048, | |||
| JP2002080327, | |||
| JP2002510302, | |||
| JP3287536, | |||
| JP4858149, | |||
| JP6160655, | |||
| JP9221442, | |||
| WO9221317, | |||
| WO9314749, | |||
| WO9855091, | |||
| WO9962483, | |||
| WO9962881, |
| Executed on | Assignor | Assignee | Conveyance | Frame | Reel | Doc |
| Dec 21 2015 | L'Oreal | (assignment on the face of the patent) | / | |||
| Jun 26 2017 | MICHELET, JEAN-FRANCOIS | L Oreal | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 043098 | /0801 | |
| Jun 26 2017 | MICHELET, FRANÇOIS | L Oreal | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 044250 | /0837 |
| Date | Maintenance Fee Events |
| May 01 2024 | M1551: Payment of Maintenance Fee, 4th Year, Large Entity. |
| Date | Maintenance Schedule |
| Nov 17 2023 | 4 years fee payment window open |
| May 17 2024 | 6 months grace period start (w surcharge) |
| Nov 17 2024 | patent expiry (for year 4) |
| Nov 17 2026 | 2 years to revive unintentionally abandoned end. (for year 4) |
| Nov 17 2027 | 8 years fee payment window open |
| May 17 2028 | 6 months grace period start (w surcharge) |
| Nov 17 2028 | patent expiry (for year 8) |
| Nov 17 2030 | 2 years to revive unintentionally abandoned end. (for year 8) |
| Nov 17 2031 | 12 years fee payment window open |
| May 17 2032 | 6 months grace period start (w surcharge) |
| Nov 17 2032 | patent expiry (for year 12) |
| Nov 17 2034 | 2 years to revive unintentionally abandoned end. (for year 12) |